Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH) is the most common histiocytic neoplasm characterized by the activation of the MAPK-pathway in the majority of cases.1 Most of the prospective studies in LCH are derived from the pediatric population. Currently, there are no United States Food and Drug Administration approved treatments for LCH. Prior studies have shown that cladribine presents an attractive option for LCH and related histiocytoses, due to its...